Details of the Drug Formulations

General Information of Drug (ID: DMGNYIH)

Drug Name
Retigabine Drug Info
Synonyms
Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester
Indication
Disease Entry ICD 11 Status REF
Behcet disease 4A62 Approved [1]
Epilepsy 8A60-8A68 Withdrawn from market [2]
Therapeutic Class
Anticonvulsants
Cross-matching ID
PubChem CID
121892
ChEBI ID
CHEBI:68584
CAS Number
150812-12-7
TTD ID
D0X7GL
VARIDT ID
DR00700
INTEDE ID
DR1407
ACDINA ID
D00263

Full List of Drug Formulations Containing This Drug

Ezogabine 400 mg tablet
Company Formulation ID FDA Description
GlaxoSmithKline F07835 Cochineal; Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Croscarmellose sodium; Lecithin, soybean; Polyvinyl alcohol; Cellulose, microcrystalline; Hypromelloses; Xanthan gum
------------------------------------------------------------------------------------
Ezogabine 50 mg tablet
Company Formulation ID FDA Description
GlaxoSmithKline F07836 Cochineal; Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Croscarmellose sodium; Lecithin, soybean; Polyvinyl alcohol; Cellulose, microcrystalline; Hypromelloses; Xanthan gum
------------------------------------------------------------------------------------
Ezogabine 300 mg tablet
Company Formulation ID FDA Description
GlaxoSmithKline F07834 Fd&c blue no. 2; Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Lecithin, soybean; Polyvinyl alcohol; Cellulose, microcrystalline; Hypromelloses; Xanthan gum
------------------------------------------------------------------------------------
Ezogabine 200 mg tablet
Company Formulation ID FDA Description
GlaxoSmithKline F07833 Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Lecithin, soybean; Polyvinyl alcohol; Cellulose, microcrystalline; Hypromelloses; Xanthan gum
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of GlaxoSmithKline.
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.